0QCV Abbvie Inc

TIDM0QCV 
 
 

FORM 8.3

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

1. KEY INFORMATION

 
Name of person dealing (Note 1)         TIAA-CREF Investment Management, 
                                        LLC/Teachers Advisors, LLC/Nuveen 
                                        Asset Management, LLC 
Company dealt in                        AbbVie Inc. 
Class of relevant security to which     US $0.01 Common Stock 
the dealings being disclosed relate 
(Note 2) 
Date of dealing                         08 May 2020 
 

2. INTERESTS AND SHORT POSITIONS

(a) Interests and short positions (following dealing) in the class ofrelevant security dealt in(Note 3)

 
                                          Long                 Short 
                                          Number        (%)    Number  (%) 
(1) Relevant securities                   17,984,609 1.218% 
(2) Derivatives (other than options) 
(3) Options and agreements to 
purchase/sell 
Total                                     17,984,609 1.218% 
 
 

(b) Interests and short positionsin relevant securitiesof the company, other than the class dealt in (Note 3)

 
Class of relevant security:                   Long           Short 
                                              Number    (%)  Number    (%) 
(1) Relevant securities                       N/A            N/A 
                                              N/A            N/A 
 (2) Derivatives (other than options) 
                                              N/A            N/A 
 (3) Options and agreements to purchase/sell 
Total                                         N/A            N/A 
 
 

1. DEALINGS (Note 4)

(a) Purchases and sales

 
 
 Purchase/sale    Number of relevant securities   Price per unit (Note 5) 
Sale             40                              $83.96 
Sale             5,502                           $83.96 
Sale             5,763                           $83.61 
Sale             2,469                           $83.97 
 

(b) Derivatives transactions (other than options transactions)

 
Product name,  Nature of transaction  Number of relevant        Price per unit 
 e.g. CFD       (Note 6)              securities (Note 7)        (Note 5) 
N/A            N/A                    N/A                       N/A 
 

(c) Options transactions in respect of existing relevant securities

(i) Writing, selling, purchasingor varying

 
Product  Writing,     Number of   Exercise  Type,      Expiry    Option money 
name,    selling,     securities  price     e.g.       date      paid/received 
e.g.     purchasing,  to which              American,            per unit 
call     varying      the option            European             (Note 5) 
option   etc.         relates               etc. 
                      (Note 7) 
N/A      N/A          N/A         N/A       N/A        N/A       N/A 
 

(ii) Exercising

 
Product name,      Number of securities  Exercise price per unit (Note 5) 
 e.g. call option 
N/A                N/A                   N/A 
 

(d) Other dealings (including transactions in respect of new securities) (Note 4)

 
Nature of transaction  Details  Price per unit 
 (Note 8)                        (if applicable) (Note 5) 
N/A                    N/A      N/A 
 

2. OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

None

Is a Supplemental Form 8 attached? (Note 9) NO

 
Date of disclosure                                           11 May 2020 
Contact name                                                 Stuart R. Brunet 
Telephone number                                             +1 (415) 882-3711 
If a connected EFM, name of offeree/offeror with which       N/A 
 connected 
If a connected EFM, state nature of connection (Note 10)     N/A 
 
 

View source version on businesswire.com: https://www.businesswire.com/news/home/20200511005503/en/

 
    CONTACT: 

TIAA-CREF

 
    SOURCE: TIAA-CREF 
Copyright Business Wire 2020 
 

(END) Dow Jones Newswires

May 11, 2020 08:05 ET (12:05 GMT)

Abbvie (LSE:0QCV)
Gráfico Histórico do Ativo
De Fev 2025 até Mar 2025

Abbvie (LSE:0QCV)
Gráfico Histórico do Ativo
De Mar 2024 até Mar 2025